BridgeBio Pharma, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
BridgeBio Pharma, Inc. (BBIO) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $680.04 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $680.04M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $882.02M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $572.14M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $645.10M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $680.04M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $882.02M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $572.14M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $645.10M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $751.10M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $542.74M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $683.24M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $407.88M 10-Q · filed 2025-10-29 |
| 2024-06-30 | $549.51M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $477.50M 10-Q · filed 2025-04-29 |
| 2023-12-31 | $394.73M 10-K · filed 2026-02-24 |
| 2023-09-30 | $524.14M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $324.64M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $435.11M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $416.88M 10-K · filed 2026-02-24 |
| 2022-09-30 | $485.79M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $472.65M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $374.19M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $396.37M 10-K · filed 2025-02-20 |
| 2021-09-30 | $183.08M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $381.13M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $473.77M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $358.68M 10-K · filed 2024-02-22 |
| 2020-09-30 | $367.39M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $541.34M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $757.47M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $364.20M 10-K · filed 2023-02-23 |
| 2019-09-30 | $414.40M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $294.23M 10-Q · filed 2020-08-11 |
| 2019-03-31 | $373.03M 10-Q · filed 2020-05-14 |
| 2018-12-31 | $436.25M 10-K · filed 2022-02-25 |
| 2018-09-30 | $212.08M 10-Q · filed 2019-11-08 |
| 2017-12-31 | $92.38M 10-K · filed 2021-02-25 |
| 2016-12-31 | $20.34M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |